FRANCE 2025 BIOTECH SKILLS PLAN

AEC Partners presents its study on the “France 2025 Biotech Skills Plan”. Sponsored by the Leem* and OPCO 2i**, this study specifies the strategic positioning of France among the 10 main families of biotechnology products and identifies needs to meet the associated skill requirements.

Read the study

*Leem: Les Entreprises du Medicament – Industry Association representing pharma companies operating in France
**OPCO2i: Opérateurs de Compétences 2i – Agency financing further education & learning in France

by admin

FRANCE 2025 BIOTECH SKILLS PLAN

AEC Partners presents its study on the Evolution of the Commercial function in the medical device sector.
Sponsored by the SNITEM and OPCO 2i, this study identifies the evolution trends and the client expectations. It provides a comprehensive mapping of the company commercial strategies. It offers job descriptions and defines capability needs.

Read the study

by admin

AEC Partners is proud to have supported EverImmune

We are proud to have supported EverImmune in its series A funding, enabling its lead product, Oncobax® AK, to enter the clinical stage in microbiota immuno-oncology

Read Press ReleaseLire le communiqué de presse

by admin

AEC Partners is proud to have supported Valbiotis

AEC Partners is proud to have supported Valbiotis with its estimated sizing of the mild to moderate hypertension market.

Read Press ReleaseLire le communiqué de presse

by admin

AEC Partners supports Biomunex pharmaceuticals with the signing of its second licensing deal as well as an equity investment in its ongoing series a funding

AEC Partners is proud to have supported Biomunex Pharmaceuticals with the signing of its second deal. After its licensing deal with Sanofi in 2019, Biomunex has now entered into a licensing and co-development agreement with Onward Therapeutics for a proprietary bispecific antibody program in hematological malignancies. The deal includes a strategic equity investment in Biomunex’s ongoing Series A round.

by admin